Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Ascletis Pharma Inc.
歌禮製藥有限公司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 1672)

VOLUNTARY ANNOUNCEMENT

ASCLETIS TO PRESENT 28-DAY MULTIPLE ASCENDING DOSE STUDY RESULTS OF ORAL SMALL MOLECULE GLP-1R AGONIST ASC30 AT THE 61ST EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD) ANNUAL MEETING

– *Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral discussion*

– *On track to report topline data from Phase IIa clinical study of ASC30 oral tablet in participants with obesity or overweight in the fourth quarter of 2025*

This announcement is made by Ascletis Pharma Inc. (the "**Company**" or "**Ascletis**", together with its subsidiaries, the "**Group**") on a voluntary basis for the purpose of keeping the shareholders of the Company and potential investors abreast of the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company announces that data from its 28-day multiple ascending dose study of its oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30 (NCT06680440) will be presented in a short oral discussion at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting held in Vienna, Austria.

Details of the Short Oral Discussion

Abstract Title: ASC30, an oral GLP-1R biased small molecule agonist demonstrated superior weight loss in participants with obesity: a 28-day multiple ascending dose study

Short Oral Discussion Sessions Event A: SO 073 The GLP-1 portfolio: diverse formulations for expanding clinical applications

Presentation Time: September 16, 2025, 12:00 – 13:00 CEST

Presentation Number: 827

"We look forward to presenting our ASC30 oral tablet clinical data to the community at this year's EASD Annual Meeting," said Jinzi Jason Wu, Ph.D., Founder, Chairman of the Board and chief executive officer of Ascletis. "We believe that these efficacy and safety data will position ASC30 oral tablet as a potentially differentiated option for the treatment of obesity."

About ASC30

ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044 without patent extensions.

About the European Association for the Study of Diabetes (EASD)

Founded in 1965 and based in Düsseldorf, Germany, the European Association for the Study of Diabetes (EASD) aims to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. The EASD Annual Meeting features groundbreaking basic research, cutting-edge clinical trial results and in-depth expert debates. The 61st EASD Annual Meeting will be held in Vienna, Austria, from September 15 to 19, 2025.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to ultimately develop, manufacture and/or commercialize ASC30 successfully.

By order of the Board
Ascletis Pharma Inc.
歌禮製藥有限公司
Jinzi Jason WU
Chairman

Hong Kong
September 2, 2025

As at the date of this announcement, the Board comprises Dr. Jinzi Jason WU and Mrs. Judy Hejingdao WU, as executive Directors; and Dr. Yizhen WEI, Mr. Jiong GU and Ms. Lin HUA, as independent non-executive Directors.